Cyclacel Pharmaceuticals PE Ratio 2006-2021 | CYCC

Current and historical p/e ratio for Cyclacel Pharmaceuticals (CYCC) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cyclacel Pharmaceuticals PE ratio as of September 23, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Cyclacel Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-09-23 5.28 0.00
2021-06-30 5.92 $-2.87 0.00
2021-03-31 7.11 $-2.89 0.00
2020-12-31 7.81 $-3.87 0.00
2020-09-30 3.65 $-5.33 0.00
2020-06-30 4.65 $-7.06 0.00
2020-03-31 7.71 $-9.68 0.00
2019-12-31 13.40 $-11.20 0.00
2019-09-30 7.93 $-11.80 0.00
2019-06-30 10.81 $-13.20 0.00
2019-03-31 18.70 $-13.20 0.00
2018-12-31 12.10 $-12.60 0.00
2018-09-30 27.40 $-9.20 0.00
2018-06-30 28.40 $-23.80 0.00
2018-03-31 27.00 $-30.60 0.00
2017-12-31 34.80 $-35.80 0.00
2017-09-30 36.60 $-49.60 0.00
2017-06-30 75.40 $-48.60 0.00
2017-03-31 73.60 $-58.80 0.00
2016-12-31 105.80 $-96.82 0.00
2016-09-30 120.00 $-107.03 0.00
2016-06-30 100.40 $-109.04 0.00
2016-03-31 92.40 $-112.85 0.00
2015-12-31 120.00 $-112.85 0.00
2015-09-30 121.32 $-139.26 0.00
2015-06-30 192.00 $-172.87 0.00
2015-03-31 216.00 $-201.68 0.00
2014-12-31 167.98 $-216.09 0.00
2014-09-30 729.60 $-211.28 0.00
2014-06-30 736.80 $-235.29 0.00
2014-03-31 883.20 $-158.46 0.00
2013-12-31 964.80 $-381.75 0.00
2013-09-30 1022.40 $-477.79 0.00
2013-06-30 708.00 $-460.98 0.00
2013-03-31 1341.60 $-585.80 0.00
2012-12-31 1454.40 $-403.30 0.00
2012-09-30 1118.40 $-379.26 0.00
2012-06-30 772.80 $-436.84 0.00
2012-03-31 1209.60 $-470.45 0.00
2011-12-31 991.20 $-537.65 0.00
2011-09-30 739.20 $-537.65 0.00
2011-06-30 2284.80 $-604.86 0.00
2011-03-31 2402.40 $-772.88 0.00
2010-12-31 2469.60 $-907.29 0.00
2010-09-30 2889.60 $-1,092.11 0.00
2010-06-30 2889.60 $-1,125.71 0.00
2010-03-31 3612.00 $-1,394.54 0.00
2009-12-31 1747.20 $-1,512.15 0.00
2009-09-30 1461.60 $-1,864.99 0.00
2009-06-30 1900.08 $-3,091.51 0.00
2009-03-31 604.80 $-3,225.92 0.00
2008-12-31 705.60 $-3,326.73 0.00
2008-09-30 2016.00 $-3,612.36 0.00
2008-06-30 3208.80 $-2,520.25 0.00
2008-03-31 5006.40 $-2,117.01 0.00
2007-12-31 9206.40 $-2,049.80 0.00
2007-09-30 9357.60 $-1,680.17 0.00
2007-06-30 10920.00 $-1,898.59 0.00
2007-03-31 13020.01 $-2,402.64 0.00
2006-12-31 11524.80 $-4,990.10 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.048B $0.000B
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71